Showing results (1031-1040 of 1,072) with videos related to
Sort By:
Pageof 108
Neuro-Oncology|November 23, 2019
Window-of-opportunity clinical trial of pembrolizumab in patients with recurrent glioblastoma reveals predominance of immune-suppressive macrophagesJohn de Groot, Marta Penas-Prado, Kristin Alfaro-Munoz, et al.Nature Communications|March 10, 2026
Dual phagocytosis-checkpoint blockade revitalizes immune surveillance in mouse models of glioblastomaJongHoon Ha, Yifan Wang, Yifan Ma, et al.Cancer Cell|August 13, 2024
Interleukin-21 engineering enhances NK cell activity against glioblastoma via CEBPDMayra Shanley, May Daher, Jinzhuang Dou, et al.Cancer Cell|September 3, 2013
Mesenchymal differentiation mediated by NF-κB promotes radiation resistance in glioblastomaKrishna P L Bhat, Veerakumar Balasubramaniyan, Brian Vaillant, et al.Nature Communications|May 2, 2024
Response of treatment-naive brain metastases to stereotactic radiosurgeryChibawanye I Ene, Christina Abi Faraj, Thomas H Beckham, et al.Nature Communications|June 12, 2020
A cancer drug atlas enables synergistic targeting of independent drug vulnerabilitiesRavi S Narayan, Piet Molenaar, Jian Teng, et al.Physical Review Letters|January 15, 2011
First dark matter results from the XENON100 experimentE Aprile, K Arisaka, F Arneodo, et al.The New England Journal of Medicine|June 29, 2022
Oncolytic DNX-2401 Virus for Pediatric Diffuse Intrinsic Pontine GliomaJaime Gállego Pérez-Larraya, Marc Garcia-Moure, Sara Labiano, et al.Nature Medicine|May 15, 2023
Oncolytic DNX-2401 virotherapy plus pembrolizumab in recurrent glioblastoma: a phase 1/2 trialFarshad Nassiri, Vikas Patil, Leeor S Yefet, et al.Science Translational Medicine|October 8, 2025
Serial multiomics uncovers anti-glioblastoma responses not evident by routine clinical analysesAlexander L Ling, Jennifer Gantchev, Michael C Prabhu, et al.Pageof 108